Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Abstract: The present invention relates to dicaffeoyl spermidine derivative glycosides, a preparation method and a use thereof. The biological activity experiments show that the dicaffeoyl spermidine derivative glycosides of the present invention have anti-oxidative activity and antiviral activity, and their activity are even better than that of a positive control drug, thus can be used as an antioxidant for the prevention and/or treatment of neurodegenerative diseases such as Senile dementia, and as an antiviral agent for the prevention and/or treatment of viral infections.

Abstract: The present disclosure provides a radio frequency (RF) source control method. An RF source includes at least one pair of a main power supply and a secondary power supply with a same frequency. The RF source control method includes dividing each process step of process steps of a plasma process into a plurality of time periods, and when performing each process step, maintaining a common exciter (CEX) phase locking delay angle of the at least one pair of the main power supply and the secondary power supply corresponding to each of the time periods at a predetermined value to provide an increased angular distribution uniformity of plasma. The RF source control method provided by the present disclosure may be used to adjust plasma distribution above a to-be-processed workpiece to average the plasma angular direction distribution of the entire process step as a whole to increase process uniformity of the to-be-processed workpiece.

Abstract: The present disclosure relates to a parallel proxy model based machine learning method for oil reservoir production. With the proposed method, multiple optimized candidate solutions can be obtained within an iteration, and then a matrix laboratory (e.g., MATLAB) is used to call numerical simulation software Eclipse in parallel to conduct actual evaluation on the candidate solutions simultaneously, so that optimization time of complex problems can be greatly reduced. With the method of the present disclosure, the efficiency of solving an oilfield production optimization problem can be speeded up to a greater extent than in the art, and the final optimization effect can be improved. Moreover, the method of the present disclosure may further be used for well pattern optimization, history matching, and so on, apart from adjusting schedules of the producers and injectors in the oilfield.

Abstract: The present invention relates to a large-scale magnetic purification system, including: a liquid storage apparatus, capable of being connected to a liquid source and a waste liquid barrel through a liquid path system; a stirring system mounted above the liquid storage apparatus, where a stirring paddle of the stirring system is inserted into the liquid storage apparatus for stirring; magnets mounted around the liquid storage apparatus; a magnet actuating mechanism for manipulating the magnets to move away from or close to the liquid storage apparatus; and a control system, connected to the liquid path system, the magnet actuating mechanism, and the stirring system and controlling the liquid path system, the magnet actuating mechanism, and the stirring system.

Abstract: This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.

Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Abstract: The present invention provides a magnetic bead purification system, including: a housing; a liquid path treatment system provided inside the housing, the liquid path treatment system being connectable to a reagent barrel and a waste liquid barrel; a sample addition needle group connected to the liquid path treatment system, the sample addition needle group being movable within the housing and connected to the liquid path treatment system, so as to receive a reagent from the liquid path treatment system or to discharge a waste liquid to the liquid path treatment system; a purification magnetic separation system, including a magnetic element, the purification magnetic separation system being controllable to apply a lateral magnetic force to a purification treatment position inside the housing or stop the application of the magnetic force by the magnetic element; and a purification station system movable between a purification treatment position inside the housing and a loading position outside the housing, the

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.

Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Abstract: Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.

Abstract: The present disclosure relates to systems and methods for updating static machine-learning models (e.g., a Doc2Vec model) without needing to retrain the models. More particularly, the present disclosure relates to systems and methods that can be used to add new data to a base model by training a client model using the new data, and transforming the vector space of the client model to align with the vector space of the base model. The base model can then be updated using the realigned client model. As such, the base model can be updated with the new data without needing to retrain the base model, which can be burdensome to processing resources, insecure, and time consuming.

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.

Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.